AU2020397893A1 - Regulatory T cell (Treg) compositions and methods for treating neurodegenerative disease - Google Patents

Regulatory T cell (Treg) compositions and methods for treating neurodegenerative disease Download PDF

Info

Publication number
AU2020397893A1
AU2020397893A1 AU2020397893A AU2020397893A AU2020397893A1 AU 2020397893 A1 AU2020397893 A1 AU 2020397893A1 AU 2020397893 A AU2020397893 A AU 2020397893A AU 2020397893 A AU2020397893 A AU 2020397893A AU 2020397893 A1 AU2020397893 A1 AU 2020397893A1
Authority
AU
Australia
Prior art keywords
tregs
expanded
cryopreserved
population
therapeutic population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020397893A
Other languages
English (en)
Other versions
AU2020397893A8 (en
Inventor
Stanley Hersh Appel
David Robert BEERS
Aaron Drew THOME
Jason Robert THONHOFF
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Methodist Hospital
Original Assignee
Methodist Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methodist Hospital filed Critical Methodist Hospital
Publication of AU2020397893A1 publication Critical patent/AU2020397893A1/en
Publication of AU2020397893A8 publication Critical patent/AU2020397893A8/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
AU2020397893A 2019-12-05 2020-12-04 Regulatory T cell (Treg) compositions and methods for treating neurodegenerative disease Pending AU2020397893A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944346P 2019-12-05 2019-12-05
US62/944,346 2019-12-05
PCT/US2020/063378 WO2021113685A2 (en) 2019-12-05 2020-12-04 Regulatory t cell (treg) compositions and methods for treating neurodegenerative disease

Publications (2)

Publication Number Publication Date
AU2020397893A1 true AU2020397893A1 (en) 2022-06-09
AU2020397893A8 AU2020397893A8 (en) 2022-06-23

Family

ID=74104193

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020397893A Pending AU2020397893A1 (en) 2019-12-05 2020-12-04 Regulatory T cell (Treg) compositions and methods for treating neurodegenerative disease

Country Status (7)

Country Link
US (1) US20230047159A1 (enExample)
EP (1) EP4069259A2 (enExample)
JP (1) JP2023504734A (enExample)
AU (1) AU2020397893A1 (enExample)
CA (1) CA3159411A1 (enExample)
MX (1) MX2022006674A (enExample)
WO (1) WO2021113685A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3221900A1 (en) * 2021-06-08 2022-12-15 Stanley Hersh Appel Methods for producing regulatory t cell (treg) populations, treg compositions and methods for treatment
WO2024233788A2 (en) * 2023-05-09 2024-11-14 The Mclean Hospital Corporation Intra-striatal co-transplantation of autologous treg and mda cells in parkinson's disease cell therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
JP5602133B2 (ja) * 2009-04-24 2014-10-08 株式会社林原 細胞障害活性及び免疫抑制活性を併せ持つヒトｔ細胞集団の製造方法
CN109715196A (zh) * 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法

Also Published As

Publication number Publication date
MX2022006674A (es) 2022-11-14
US20230047159A1 (en) 2023-02-16
CA3159411A1 (en) 2021-06-10
WO2021113685A3 (en) 2021-07-08
WO2021113685A2 (en) 2021-06-10
EP4069259A2 (en) 2022-10-12
JP2023504734A (ja) 2023-02-06
AU2020397893A8 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
Brestoff et al. Intercellular mitochondria transfer to macrophages regulates white adipose tissue homeostasis and is impaired in obesity
Selleri et al. Human mesenchymal stromal cell-secreted lactate induces M2-macrophage differentiation by metabolic reprogramming
ES2579762T3 (es) Tratamiento del cáncer combinando agente linfo - reductor con CLTs y citoquinas
Chang et al. Single-cell transcriptomic identified HIF1A as a target for attenuating acute rejection after heart transplantation
JP6449148B2 (ja) 免疫抑制細胞作成方法、及び、免疫抑制細胞を含む組成物の使用方法
KR20190085000A (ko) 면역억제성 간엽 세포 및 그것의 형성 방법
AU2016250570A1 (en) Therapeutic pooled blood apoptotic cell preparations and uses thereof
US20250333764A1 (en) Engineered regulatory t cells
US20130302293A1 (en) Compositions, cells, kits and methods for autologous stem cell therapy
AU2020397893A1 (en) Regulatory T cell (Treg) compositions and methods for treating neurodegenerative disease
Caielli et al. An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
CA3210656A1 (en) Regulatory t cell (treg) extracellular vesicle compositions and methods
Li et al. Engineered immunosuppressive dendritic cells protect against cardiac remodelling
CN115724997B (zh) 一种抗cd97嵌合抗原受体、基因、表达载体、t细胞及应用
US20240093150A1 (en) Improved t-cells for cancer therapy using amino acid starvation pathways
US8992933B2 (en) Methods for activating T cells and modulating an immune response
Schlaweck et al. The CCR4/CCL17 axis drives intestinal acute Graft versus Host disease after allogeneic bone marrow transplantation
WO2026088096A1 (en) Treatment of systemic sclerosis using a population of cd19 car-expressing cells
Chan Investigating the Effects of Polarized Monocytes/Macrophages in Osteoarthritis
Cartura et al. Immunomodulatory endothelial cells contribute to T cell recruitment and activation through antigen presentation on MHC class II
Albericio et al. Comparative Proteomic Analysis of Nuclear and Cytoplasmic Compartments in Human Cardiac Progenitor Cells. Functional Evaluation of IL1A and IMP3
Leung et al. RNA helicase Ddx21 safeguards fetal HSPC expansion by recruiting Kdm5a to epigenetically sustain ribosomal and hematopoietic gene transcription
Robb Evaluating the influence of mesenchymal stromal cell critical quality attributes, clinical phenotype and molecular endotype features on treatment efficacy in osteoarthritis
Bakheet Conventional dendritic cells for regeneration of immune tolerance
WO2025202287A1 (en) Method of producing macrophages

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 36 , NO 23 , PAGE(S) 3291 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME THE METHODIST HOSPITAL SYSTEM, APPLICATION NO. 2020397893, UNDER INID (71) CORRECT THE APPLICANT NAME TO THE METHODIST HOSPITAL